Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study
Launched by UNIVERSITY MEDICAL CENTER HO CHI MINH CITY (UMC) · Jul 17, 2024
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the characteristics and treatment of patients with heart failure in Vietnam. Researchers want to learn more about how patients are cared for during their hospital stay and how they continue to receive treatment and manage their health after leaving the hospital. They will collect information about patients’ health at three different times: when they are discharged, and again at 1 month, 3 months, and 12 months after leaving the hospital.
To participate in this study, individuals need to be at least 18 years old and have been diagnosed with heart failure when they were discharged from the hospital. Specifically, they should have a measurement from a heart test showing that their heart’s ability to pump blood is reduced. Patients must also be able to communicate with healthcare staff and live in Vietnam after they leave the hospital. If eligible, participants can expect to share their health information over the course of the year, which will help improve the understanding and treatment of heart failure in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 years and older
- • Diagnosed with heart failure at the time of discharge
- • Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%
- Exclusion Criteria:
- • Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.)
- • Patients do not reside in Vietnam after discharge
About University Medical Center Ho Chi Minh City (Umc)
University Medical Center Ho Chi Minh City (UMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMC focuses on enhancing patient outcomes and contributing to the medical community by exploring cutting-edge treatments and therapies. The center fosters collaboration among healthcare professionals, researchers, and industry partners, ensuring a robust framework for conducting high-quality clinical research. With a commitment to ethical standards and patient safety, UMC plays a vital role in the development of medical knowledge and the improvement of health services in Vietnam and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ho Chi Minh City, , Vietnam
Patients applied
Trial Officials
Cong Thanh Nguyen, MD, MSc
Study Chair
University Medical Center Ho Chi Minh City
Thanh Hai Nam Phan, MD, MSc
Study Chair
University Medical Center Ho Chi Minh City
Quang Binh Truong, Professor
Study Director
University of Medicine and Pharmacy at Ho Chi Minh City
Hoang Vu Vu, PhD
Principal Investigator
University of Medicine and Pharmacy at Ho Chi Minh City
Dang Duy Quang Pham, MD, MSc
Study Chair
University Medical Center Ho Chi Minh City
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported